A multicenter retrospective analysis of the antifungal susceptibility patterns of *Candida* species and the predictive factors of mortality in South Korean patients with candidemia

In Young Jung, MD\(^a\), Su Jin Jeong, MD, PhD\(^b\),*, Young Keun Kim, MD, PhD\(^a\), Hyo Youl Kim, MD, PhD\(^a\), Young Goo Song, MD, PhD\(^b\), June Myung Kim, MD, PhD\(^b\), Jun Yong Choi, MD, PhD\(^b\)

Abstract
As detection rates of non-albicans *Candida* species are increasing, determining their pathogen profiles and antifungal susceptibility patterns is important for antifungal treatment selection. We identified the antifungal susceptibility patterns and predictive factors for mortality in candidemia.

A multicenter retrospective analysis of patients with at least 1 blood culture positive for *Candida* species was conducted. *Candida* species were classified into 3 groups (group A, *Candida albicans*; group B, *Candida tropicalis*, and *Candida parapsilosis*; group C, *Candida glabrata* and *Candida krusei*) to analyze the susceptibility patterns, first-line antifungal administered, and mortality. Univariate and multivariate comparisons between outcomes were performed to identify mortality risk factors.

In total, 317 patients were identified, and 136 (42.9%) had recorded mortality. Echinocandin susceptibility was higher for group A than group B (111/111 [100%] vs 77/94 [81.9%], \(P < .001\)). Moreover, group A demonstrated higher fluconazole susceptibility (144/149 [96.6%] vs 39/55 [70.9%], \(P < .001\)) and lower mortality (68 [45.3%] vs 34 [61.8%], \(P = .036\)) than those of group C. In the multivariate analysis, the sequential organ failure assessment score (odds ratio OR 1.351, 95% confidence interval 1.067–1.711, \(P = 0.013\) and positive blood culture on day 7 of hospitalization (odds ratio 5.506, 95% confidence interval, 1.697–17.860, \(P = .004\)) were associated with a higher risk of mortality.

Patients with higher sequential organ failure assessment scores and sustained positive blood cultures have an increased risk of mortality.

**Abbreviations:** *C. albicans* = *Candida albicans*, *C. glabrata* = *Candida glabrata*, *C. krusei* = *Candida krusei*, *C. parapsilosis* = *Candida parapsilosis*, *C. tropicalis* = *Candida tropicalis*, CI = confidence interval, CLSI = Clinical and Laboratory Standards Institute, CVC = central venous catheters, EUR = Europe, ICU = intensive care unit, MICs = minimal inhibitory concentrations, NA = North America, OR = odds ratio, SOFA = sequential organ failure assessment.

**Keywords:** antifungal, candida, mortality, susceptibility

1. Introduction
*Candida* species are normal flora of the gastrointestinal and genitourinary tracts. However, in hosts with a decreased immune response, widespread dissemination can result in multi-organ failure.\(^{[1]}\) The term candidemia refers to the presence of *Candida* species in the blood.\(^{[2]}\) *Candida* species identified from blood should never be considered contaminants, because that is the most common manifestation of invasive candidiasis.\(^{[2]}\) Risk factors for candidemia include patients who have been treated in an intensive care unit (ICU) and those who are immunocompro-
mised. Identified risk factors for developing candidemia are patients in the ICU with indwelling central venous catheters (CVC), those receiving total parental nutrition, and those who have undergone gastrointestinal procedures.

Although infection with Candida albicans (C albicans) is most common, the identification of the casual species is important, because some species are more resistant to azole antifungal agents. The isolation of non-albicans Candida species has been increasing, and they have been frequently identified in the following order: Candida glabrata (C glabrata) and Candida parapsilosis, followed by Candida tropicalis (C tropicalis) and Candida krusei (C krusei). Some C glabrata isolates are resistant to fluconazole, and all C krusei isolates are considered to be intrinsically resistant to fluconazole. The minimal inhibitory concentrations (MICs) for echinocandins for Candida parapsilosis (C parapsilosis) are higher than those of other Candida species. Moreover, resistance to fluconazole is highly predictive of resistance to voriconazole. Therefore, the identification of changes in pathogen profiles and antifungal susceptibilities is important for antifungal treatment selection. Our study specifically compared the clinical, epidemiological, and antifungal susceptibility patterns in candidemia and identified risk factors for mortality.

2. Materials and methods

2.1. Study population and definitions

A multicenter retrospective analysis of episodes of candidemia in adults, collected from the electronic databases of 2 tertiary care hospitals in South Korea, was performed over a 4-year period (2012–2013). Patients with at least 1 positive blood culture for a Candida species were included in the analysis. Patients with isolated yeasts other than Candida species were excluded from the study.

Intravenous catheter-related candidemia was defined in patients who had an intravascular device and ≥1 positive blood culture result, such that the same organism was isolated from the catheter and a peripheral blood culture, with clinical manifestations of infection (fever, chills, and/or hypotension) and no other apparent source for the bloodstream infection. An intra-abdominal source of candidemia was considered for the patients who had a recent abdominal surgery or intra-abdominal events, such as peritonitis, abdominal abscess, and a purulent or necrotic infection at sites of gastrointestinal perforation or anastomotic leak, as confirmed by computed tomography scans. Cardiovascular disease in patients was defined as the presence of hypertension, valvular heart disease, ischemic heart disease, or heart failure. Central nervous system disorder in patients was defined by a history of cerebrovascular accident or hemorrhage. Renal disease in patients was defined by chronic renal failure, stage 3 or 4, requiring hemodialysis or peritoneal dialysis. Lung disease in patients was defined as the presence of asthma, chronic obstructive lung disease, or idiopathic pulmonary fibrosis. Hematologic disease in patients was defined by aplastic anemia, lymphoma, or leukemia. The use of echinocandin was defined in patients who received first-line antifungal treatment with caspofungin, anidulafungin, or micafungin.

The demographic data, comorbidities, hospitalization and ICU stay, laboratory results, treatment outcomes, Candida species distribution, antifungal susceptibility results, first-line antifungal agents administered, and the complications (endocarditis, bone or joint infection, hepatosplenic candidiasis, and endophthalmitis) related to the candidemia were compared among the outcomes. The severity of illness was estimated by the sequential organ failure assessment (SOFA) score and the Charlson index. The laboratory data obtained on the first day of admission were analyzed. The presence of CVC insertion at the time of the positive blood culture and whether the patient was admitted to the ICU or the general ward were compared between outcomes. Blood culture results positive for a Candida species, obtained on the 7th, 14th, and 28th hospital day, were analyzed. The appropriate antifungal treatment was considered when the treatment was started within 48 hours, after the first blood culture was performed. Univariate and multivariate comparisons between outcomes were performed.

Candida species were classified as C albicans (group A) and non-albicans Candida species groups (groups B and C). Among the non-albicans group, species with reduced susceptibility to fluconazole were classified as group C (C glabrata and C krusei), and species susceptible to fluconazole classified as group B (C tropicalis and C parapsilosis). The clinical and demographic factors, susceptibility patterns, first-line antifungal treatment, and mortality of each group were analyzed.

2.2. Laboratory testing

Using the BACTEC 860 system (Becton Dickinson, Inc., Sparks, MD), isolated Candida were detected from blood cultures. Candida species were identified using the API-32C system (BioMerieux Vitek, Inc., St. Louis, MO). The commercial VITEK-2 yeast susceptibility test (BioMerieux, Hazelwood, MO) was used to derive the MICs for Candida species. Susceptibility to echinocandin and fluconazole was defined as follows according to the clinical breakpoints for interpreting the MICs from the Clinical and Laboratory Standards Institute (CLSI) guidelines. Susceptibility to echinocandins was defined in isolates of C albicans, C tropicalis, and C krusei with an MIC ≤0.25 mcg/mL, and C parapsilosis with an MIC ≤2 mcg/mL for all 3 echinocandins (anidulafungin, caspofungin, and micafungin). C glabrata isolates with an MIC ≤0.12 mcg/mL to caspofungin and anidulafungin, and an MIC ≤0.06 mcg/mL to micafungin were considered susceptible. The CLSI does not currently provide a susceptible breakpoint of fluconazole for C glabrata, with the intermediate breakpoint defined as MIC ≥32 and resistance as MIC ≥64. Susceptible was an MIC ≤2 mcg/mL for fluconazole in all species of Candida, except for C glabrata and C krusei (Supplementary Table 1, http://links.lww.com/MD/ D953).

The authors confirm that the ethical policies of the journal, as noted on the journal’s author guidelines page, have been adhered to and the appropriate ethical review committee approval has been received.

2.3. Statistical analysis

Categorical variables have been presented as numbers and percentages, and continuous variables have been expressed as the mean±standard deviation, unless otherwise indicated. Categorical variables were compared using a χ2 analysis, and continuous variables with normal distributions were compared using the Student t test. Single linear univariate correlations (Pearson correlation coefficients) and stepwise multivariate regression analyses were performed to evaluate the relationship between
mortality and other variables. The covariates inserted in this model included the variables that differed with a $P < .05$ in the univariate analysis, which ensured the absence of significant multicollinearity. Multiple differences among groups of $C$ albicans and non-albicans species were evaluated using a 1-way Analysis of Variance (ANOVA) with Tukey multiple comparison test. All categories were calculated as a percentage with a 95% confidence interval (CI). All statistical tests were performed using IBM SPSS software for Windows, version 20. $P$-values $< .05$ were considered statistically significant.

3. Results

During the study period, a total of 317 patients (88 cases originating from indwelling intravenous catheter, 89 cases from an intra-abdominal source, and 140 cases with an unidentifiable source of candidemia) were analyzed. Among these patients, mortality was observed for 136 (42.9%) patients.

The baseline characteristics and demographic data of the study population are presented in Table 1. Among the study patients, 198 (62.5%) were male with a median age of 68.3 ± 13.5 years.

### Table 1

| Characteristic             | Total (n=317) | Survival (n=181) | Mortality (n=136) | $P$-value |
|----------------------------|---------------|------------------|-------------------|-----------|
| Gender, male               | 198 (62.5)    | 105 (58.0)       | 93 (68.4)         | .059†     |
| Age, yr                    | 68.3 ± 13.5   | 68.1 ± 13.4      | 68.8 ± 13.7       | .006†     |
| BMI                        | 21.8 ± 4.1    | 21.5 ± 3.9       | 22.2 ± 4.2        | .169‡     |
| Hospital, d                | 52.4 ± 63.4   | 62.9 ± 74.6      | 47.2 ± 43.0       | .003‡     |
| ICU, d                     | 19.5 ± 24.2   | 16.8 ± 21.4      | 22.2 ± 26.8       | .009‡     |
| Charlson index             | 3.4 ± 1.9     | 3.1 ± 1.8        | 3.8 ± 1.9         | .003†     |
| SOFA score                 | 4.3 ± 3.9     | 2.9 ± 2.9        | 6.2 ± 4.3         | <.001†    |
| Underlying disease         |               |                  |                   |           |
| Cardiovascular disease     | 179 (56.5)    | 100 (55.2)       | 79 (58.1)         | .614‡     |
| CNS disorder               | 91 (28.7)     | 51 (25.2)        | 40 (29.4)         | .810‡     |
| Solid organ cancer         | 109 (34.9)    | 66 (36.5)        | 43 (31.9)         | .394‡     |
| Renal disease              | 96 (30.3)     | 56 (30.9)        | 40 (44.1)         | <.001†    |
| Liver disease              | 59 (18.6)     | 33 (18.2)        | 26 (19.1)         | .841‡     |
| Lung disease               | 164 (51.7)    | 71 (39.2)        | 93 (68.4)         | <.001†    |
| Solid organ transplantation | 8 (2.5)       | 6 (3.3)          | 2 (1.5)           | .474‡     |
| Hematologic disease        | 110 (34.7)    | 48 (26.5)        | 62 (45.6)         | <.001†    |
| Risk factor for infection  |               |                  |                   |           |
| CVC                        | 149 (47.0)    | 74 (40.9)        | 75 (55.1)         | .012‡     |
| ICU admission              | 116 (36.6)    | 49 (27.1)        | 67 (49.3)         | <.001†    |
| Laboratory data            |               |                  |                   |           |
| WBC (×10³/L)               | 1949 ± 5023   | 2120 ± 4798      | 1722 ± 5316       | .486†     |
| Hb (g/dL)                  | 10.3 ± 2.3    | 10.5 ± 2.7       | 10.1 ± 1.6        | .071†     |
| Platelet (×10³/L)          | 40,098 ± 101,745 | 48,676 ± 105,095 | 28,681 ± 96306  | .080‡     |
| AST (U/L)                  | 121.3 ± 594.0 | 51.4 ± 64.2      | 224.7 ± 926.8     | .008†     |
| ALT (U/L)                  | 54.6 ± 105.2  | 40.4 ± 99.1      | 75.9 ± 147.8      | .028†     |
| Total bilirubin            | 10.9 ± 131.3  | 2.1 ± 7.6        | 23.9 ± 206.4      | .299†     |
| BUN (mg/dL)                | 33.8 ± 20.1   | 26.4 ± 25.7      | 43.7 ± 30.6       | <.001†    |
| Creatinine (mg/dL)         | 1.6 ± 2.6     | 1.5 ± 3.2        | 1.7 ± 1.6         | .690‡     |
| Microbiological data       |               |                  |                   |           |
| Culture positive on day 7  | 42 (48.8)     | 21 (35.6)        | 21 (77.8)         | <.001†    |
| Culture positive on day 14 | 10 (18.5)     | 7 (17.1)         | 3 (23.1)          | .689‡     |
| Culture positive on day 28 | 2 (6.5)       | 1 (4.3)          | 1 (12.5)          | .456‡     |
| Complication related to candidemia | 9 (2.8) | 7 (3.9) | 2 (1.5) | .309‡ |

The data were expressed as the mean ± SD or median (interquartile range) or number of patients (%).

ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, CNS = central nervous system, CVC = central venous catheter, Hb = haemoglobin, ICU = intensive care unit, SOFA = sequential organ failure assessment, WBC = white blood cell.

† Student $t$ test.
‡ Fisher exact test.
**Table 2**

Predictive factors for mortality.

| Variables                              | Univariate analysis |          |          |          | Multivariate analysis |          |          |
|----------------------------------------|---------------------|----------|----------|----------|-----------------------|----------|----------|
|                                        | OR                  | 95% CI   | P-value  | OR       | 95% CI                | P-value  |         |
| Hematologic disease                    | 2.322               | 1.448–3.722 | <.001   | 0.861   | 0.218–3.399             | .830     |         |
| Presence of CVC                        | 1.778               | 1.154–2.767 | .012    | 0.767   | 0.206–2.852             | .767     |         |
| ICU admission                          | 2.616               | 1.630–4.184 | <.001   | 1.371   | 0.303–6.200             | .682     |         |
| Hospital, days                         | 0.905               | 0.900–1.000 | .037    | 0.997   | 0.986–1.000             | .655     |         |
| SOFA score                             | 1.294               | 1.199–1.396 | <.001   | 1.351   | 1.067–1.711             | .013     |         |
| Charlson index                         | 1.201               | 1.063–1.357 | .003    |         |                       |         |         |
| Culture positive on day 7              | 6.333               | 2.211–18.139 | .001   | 5.506   | 1.697–17.860             | .004     |         |
| Candida species                        |                     |          |          |          |                       |         |         |
| Candida albicans                       | 1                   |          |          |         |                       |         |         |
| Candida tropicalis, Candida parapsilosis| 0.612               | 0.363–1.033 | .066    |         |                       |         |         |
| Candida glabrata, Candida krusei       | 1.665               | 0.872–3.181 | 1.22    |         |                       |         |         |
| Treatment                              | No antifungal        | 1        |          |         |                       |         |         |
| Fluconazole                            | 0.636               | 0.383–1.055 | .080    |         |                       |         |         |
| Echinocandin                           | 0.148               | 0.041–0.541 | .004    |         |                       |         |         |

CI = confidence interval, CVC = central venous catheter, ICU = intensive care unit, Logistic regression analysis, OR = odds ratio, SOFA = sequential organ failure assessment.

Candida species. Although the univariate analysis showed that echinocandin use resulted in a lower risk of mortality compared to no antifungal treatment (OR 0.148, 95% CI 0.041–0.541, P = .004), there was no statistically significant difference in the multivariate analysis.

Table 3 presents the characteristics of the C. albicans (group A) and non-albicans Candida species groups (groups B and C). The isolates were identified as C. albicans, C. parapsilosis or C. tropicalis, and C. glabrata or C. krusei in 150, 112, and 55 cases (C. albicans [n = 150], C. parapsilosis [n = 60], C. tropicalis [n = 52], C. glabrata [n = 47], and C. krusei [n = 8], respectively. No other Candida species were isolated. No multiple Candida isolates were identified from the same patient, and no mixed infections were identified. Susceptibility to echinocandin was higher for group A than group B (111/111 [100%] vs 77/94 [81.9%], P < .001). Group A presented higher susceptibility to fluconazole than that of group C (144/149 [96.6%] vs 39/55 [70.9%], P < .001). There was no difference in mortality between groups A and B. However, lower mortality was observed for group A than group C (68 [45.3%] vs 34 [61.8%], P = .036).

Figure 1 presents the percentages for echinocandin and fluconazole susceptibility for each group of Candida species.

### 4. Discussion

Candidemia is 1 of the most common causes of health-care associated bloodstream infections.[16] Among 1,314 Candida isolates tested from the Asia-Pacific region, C. albicans (46.0%) was the most commonly isolated species followed by C. glabrata (17.9%), C. tropicalis (14.1%), C. parapsilosis (12.9%), and C. krusei (1.8%).[12] Although C. albicans is the most commonly isolated species, an increase in non-albicans Candida species has been observed worldwide.[16] C. glabrata was the most common non-C. albicans species detected in all geographic regions except for Latin America, where C. parapsilosis and C. tropicalis were more common.[12] Both Europe (EUR) and North America (NA) demonstrated similar species distribution with C. albicans (EUR 52.5%, NA 42.7%) the most commonly isolated species followed by C. glabrata (EUR 16.0%, NA 24.3%).[12] C. tropicalis was 3.4% of bloodstream isolates of C. glabrata from North America (10.6%) and in C. tropicalis from the Asia-Pacific region (9.2%).[12] Fluconazole resistance for C. albicans was low in both North America (0.4%), and Asia-Pacific regions (0.2%).[12] In this study, 3.4% of C. albicans were resistant to fluconazole, with C. glabrata, and C. krusei isolates exhibiting higher resistance to fluconazole than C. albicans. Due to an altered cytochrome P450 isoenzyme, C. krusei is intrinsically resistant to fluconazole.[18] In a large international surveillance study that included 326 bloodstream isolates of C. krusei, all of the isolates were susceptible to echinocandins.[19] Echinocandin resistance ranged from 3.5% for C. glabrata to 0.1% for C. albicans and C. parapsilosis across the globe.[12] In the present study, C. tropicalis and C. parapsilosis isolates were less susceptible to echinocandins, as has been reported in prior studies.[17,20] Prior studies have identified increasing age, higher Acute Physiology and Chronic Health Evaluation II scores, the Candida species, underlying renal dysfunction, and the primary antifungal agent selected as factors that are associated with an increased risk of mortality.[21–23] Although a higher SOFA score demonstrated an association with an increased risk of mortality, which has been shown in prior studies, there was no statistically significant difference in mortality among the Candida species or the primary antifungal agent administered.
Table 3
Characteristics of *C. albicans* and non-*C. albicans* *Candida* species.

|                      | *C. albicans* | *C. parapsilosis, C. tropicalis* | *C. glabrata* | Non-albicans groups |
|----------------------|---------------|--------------------------------|---------------|---------------------|
|                      | Group A (n=150) | Group B (n=112) | C (n=55) | P-value | P-value | P-value |
| Age, yr              | 74.6±13.21     | 69.2±13.31       | 73.8±14.6  | .004    | .004    | .923    |
| Gender, male         | 88 (58.7)      | 76 (67.9)        | 34 (61.8)  | .407    | .128    | .684    |
| Hospital, d          | 48.9±3.7       | 65.9±8.76        | 57.4±43.1  | 1.000   | .082    | .673    |
| ICU, d               | 18.8±21.6      | 21.4±29.2        | 17.7±19.7  | .652    | .716    | .970    |
| SOFA score           | 4.4±4.0        | 4.2±3.9          | 4.3±3.5    | .885    | .874    | .979    |
| Charlson index       | 3.4±1.8        | 3.1±1.7          | 3.8±2.2    | .072    | .382    | .383    |
| Underlying disease   |               |                  |            |         |         |         |
| Cardiovascular disease| 88 (58.7)     | 59 (52.7)        | 32 (58.2)  | .721    | .334    | .960    |
| CNS disorder         | 39 (26.0)      | 38 (33.9)        | 14 (25.5)  | .706    | .163    | .937    |
| Solid organ cancer   | 50 (33.6)      | 37 (33.0)        | 22 (40.0)  | .484    | .930    | .393    |
| Renal disease        | 48 (32.0)      | 28 (25.0)        | 20 (36.4)  | .900    | .217    | .557    |
| Liver disease        | 28 (18.7)      | 21 (18.8)        | 10 (18.2)  | .951    | .986    | .937    |
| Lung disease         | 89 (59.3)      | 51 (45.5)        | 24 (43.8)  | .017    | .027    | .045    |
| Solid organ transplantation | 2 (1.3) | 5 (4.5)     | 1 (1.8)    | .503    | .141    | .100    |
| Hematologic malignancy| 2 (1.3)       | 6 (5.4)          | 4 (7.3)    | .028    | .077    | .046    |
| Connective tissue disease | 9 (6.0) | 15 (13.4)       | 11 (20.0)  | .003    | .04     | .003    |
| Risk factor for infection |            |                  |            |         |         |         |
| CVC in place at time of positive blood culture | 80 (53.3) | 48 (42.9)       | 21 (38.2)  | .031    | .093    | .055    |
| ICU admission        | 59 (39.3)      | 43 (38.4)        | 14 (25.5)  | .110    | .877    | .066    |
| Laboratory data      |               |                  |            |         |         |         |
| WBC (×10^9/L)        | 1874±4411      | 2100±5763        | 1847±5058  | .925    | .931    | .999    |
| Hb (g/dL)            | 10.4±2.9       | 10.3±1.5         | 10.1±2.1   | .611    | .883    | .589    |
| Platelet (×10^9/L)   | 3576±81745     | 49810±123932     | 32381±89167| .446    | .508    | .977    |
| AST (U/L)            | 85.6±192.1     | 200.8±667.6      | 54.8±63.1  | .287    | .336    | .964    |
| ALT (U/L)            | 55.6±116.9     | 57.7±108.0       | 39.9±49.2  | .631    | .990    | .678    |
| Total bilirubin       | 20.7±194.0     | 3.05±93.2        | 1.86±49.3  | .568    | .616    | .701    |
| BUN (mg/dL)          | 37.0±31.11     | 28.8±24.91       | 35.2±24.4  | .059    | .05     | .904    |
| Creatinine (mg/dL)   | 1.4±1.4        | 1.8±3.9          | 1.6±1.7    | .570    | .544    | .880    |
| Microbiological data |               |                  |            |         |         |         |
| Culture positive on day 7 | 18 (31.0) | 13 (28.3)      | 11 (50.0)  | .369    | .183    | .285    |
| Culture positive on day 14 | 2 (6.7) | 6 (24.0)       | 2 (15.4)   | .768    | 1.000   | .658    |
| Culture positive on day 28 | 1 (5.0) | 1 (5.0)        | 0 (0)      | .368    | 1.000   | .464    |
| Susceptibility        |               |                  |            |         |         |         |
| Echinocandin S (n=251) | 111/111 (100) | 77/94 (81.9)    | 45/46 (97.8) | .064    | <.001   | .293    |
| Fluconazole S (n=316) | 144/149 (86.6) | 108/112 (96.4) | 39/55 (70.9) | <.001   | 1.000   | <.001   |
| Treatment             |               |                  |            |         |         |         |
| Echinocandin S (n=67) | 30 (20.0)     | 22 (19.6)        | 15 (27.3)  | .350    | 1.000   | .265    |
| Fluconazole S (n=236) | 114 (76.0)    | 88 (76.6)        | 34 (61.8)  | .110    | .624    | .045    |
| Complication          | 4 (2.7)        | 2 (1.8)          | 3 (5.5)    | .443    | 1.000   | .388    |
| Mortality             | 68 (45.3)      | 34 (30.4)        | 34 (61.8)  | .305    | 1.000   | .036    |

The data were expressed as the mean±SD or median (interquartile range) or number (%) of patients.

C. albicans = *Candida albicans*, C. glabrata = *Candida glabrata*, C. krusei = *Candida krusei*, C. parapsilosis = *Candida parapsilosis*, C. tropicalis = *Candida tropicalis*, CVC = central venous catheter, ICU = intensive care unit, R = resistant, S = susceptible, SOFA = sequential organ failure assessment.

1. *P*-value between Group A and Group B.
2. *P*-value between Group A and Group C. The *P*-value was evaluated by 1-way ANOVA among the 3 groups.
3. Linear by linear association.
4. Fisher exact test.
5. Statistically significant difference between 2 groups based on Tukey post hoc test.

In this study, positive blood culture results obtained 1 week after hospitalization were associated with a nearly 5 times greater risk of mortality. For cases of deep-seated candidemia, blood culture positivity is estimated to be less than 50%.^{1,24} Considering the low sensitivity of culture positivity in deep-seated candidemia, we believe that this finding raises awareness for clinicians, by indicating that *Candida* species isolated from blood should never be considered contaminants, and that patients with a positive blood culture after 1 week are at higher risk for a poor outcome.

There are several limitations to this study. First, this study is limited by its retrospective nature. Second, the clinical MIC breakpoints for both the echinocandins and fluconazole were defined according to the CLSI guidelines. Third, describing geometric means, MIC ranges, MIC 50 and MIC 90 values was not possible in this study.

The results of our study demonstrate the antifungal susceptibility patterns of *Candida* species at 2 hospitals in South Korea. Moreover, patients with higher SOFA scores at the time of
admission and a positive culture on the 7th day of hospitalization are at an increased risk of mortality.

Author contributions

IJY designed the study and acquired data, analyzed and interpreted the data, drafted the initial manuscript, reviewed, and critically revised and approved the final manuscript as submitted. SJS conceptualized the study and is responsible for the content of the manuscript, including the data and analysis. YKK, HYK, YGS, JMK, and JYC provided statistical assistance and revised and approved the final manuscript. All authors read and approved the final manuscript.

References

[1] Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1–50.

[2] Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005;41:1455–60.

[3] Kullberg BJ, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2020;69:1595–703.

[4] Messer SA, Jones RN, Fritsch TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2003). J Clin Microbiol 2006;44:1782–7.

[5] Lyon GM, Karatela S, Sunay S, et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol 2010;48:1270–5.

[6] Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011;14:39–76.

[7] Ghannoun MA, Clinical, Laboratory Standards I. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement M27-S3 Vol.28 No. 15, Volume 28, No. 15.

[8] Mermod LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1–45.

[9] Grim SA, Berger K, Teng C, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2011;67:707–14.

[10] Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011;14:364–76.

[11] Ko J-H, Jung DS, Lee JY, et al. Changing epidemiology of non-albicans candidemia in Korea. J Infect Chemother 2019;25:886–91.

[12] Adams E, Quinn M, Tsay S, et al. Candida auris in healthcare facilities, New York, USA, 2013–2017. Emerg Infect Dis 2018;24:1816–24.

[13] Tsay S, Kallen A, Jackson RR, et al. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis 2018;66:306–11.

[14] Lee WG, Shin JH, UH Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol 2011;49:3139–42.

[15] Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses 2015;58:2–13.

[16] Pfaller M, Andes D, Diekema D, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010;13:80–95.

[17] Pfaller M, Diekema D, Gibbs D, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program, 2001 to 2005. J Clin Microbiol 2008;46:515–21.

[18] Pfaller M, Diekema D, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011;14:364–76.

[19] Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis 2012;74:323–31.

[20] Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012;54:1110–22.

[21] Schuster MG, Mebolom A, Lloyd L, et al. Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. J Infect 2013;66:278–84.

[22] Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013;56:1284–92.